Paula I. González-Ericsson

Author

Vanderbilt University Medical Center ORCID

Also Known As

Balko, Justin M., Elena Provenzano, Ericsson, Paula I. González-, P Ericsson-Gonzalez, P Gonzalez Ericsson, P Gonzalez-Ericsson, Paul Jank, Paula Ericsson-Gonzalez, Paula G. Ericsson, Paula González Ericsson

395

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Medical Center Vanderbilt University The University of Texas Southwestern Medical Center Breast Cancer Research Foundation Dana-Farber Cancer Institute

About

Paula I. González-Ericsson is an author at Vanderbilt University Medical Center specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	625
2	Cell Biology	9	9	576
3	Immunology	6	6	459
4	Pathology	4	4	220
5	Health Sciences	2	2	44

Paula I. González-Ericsson

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data Francesca Finotello, Clemens Mayer, Christina Plattner, Genome Medicine	2019	1.6K
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer Luigi Formisano, Yao Lu, Alberto Servetto, Nature Communications	2019	383
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer Na Luo, Mellissa J. Nixon, Paula I. González-Ericsson, Nature Communications	2018	254
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes Brian D. Lehmann, Antonio Colaprico, Tiago C. Silva, Nature Communications	2021	244
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer, Cancer Research	2017	224
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Zuzana Kos, Elvire Roblin, Rim S. Kim, npj Breast Cancer	2020	190
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers David L. Elion, Max E. Jacobson, Donna J. Hicks, Cancer Research	2018	175
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis Douglas B. Johnson, Wyatt J. McDonnell, Paula I. González-Ericsson, Nature Medicine ImmunologyAntiviral ResponsePathologyAutoimmunityT Cell Immunity	2019	171
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement Douglas B. Johnson, Mellissa J. Nixon, Yu Wang, JCI Insight ImmunologyImmunoeditingImmunologic MechanismAntigen ProcessingImmunotherapy	2018	155
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer Brian D. Lehmann, Vandana G. Abramson, Melinda E. Sanders, Clinical Cancer Research	2019	142

Page 1